<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The AMEX method of fixation permitted the serial study of c-myc expression in bone-marrow (BM) biopsies obtained from 6 patients with <z:hpo ids='HP_0011009'>acute</z:hpo> myelogenous <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and one with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) during therapy with various cytotoxic and bioactive agents </plain></SENT>
<SENT sid="1" pm="."><plain>BM cytotoxic therapy and therapy with bioactive agents was capable of altering c-myc expression in vivo </plain></SENT>
<SENT sid="2" pm="."><plain>While cytotoxic therapy was generally associated with a fall in myc expression, it did not produce a dramatic effect on myc expression </plain></SENT>
<SENT sid="3" pm="."><plain>Recombinant human granulocyte-macrophage colony-stimulating factor (RhGM-CSF) can increase and <z:chebi fb="2" ids="26536">retinoic acid</z:chebi>/alpha-interferon can decrease c-myc expression in myeloid cells in vivo </plain></SENT>
</text></document>